Developing an automatic microfluidic platform using ‘ferrobots’
A new microfluidic technology has been developed by researchers, which utilises magnetic ferrobots to automate chemical analyses and assays.
List view / Grid view
Articles
Discovering and designing drugs with artificial intelligence
The first drug designed using artificial intelligence (AI) has moved into its Phase I trial. Professor Andrew Hopkins of Exscientia explains how an algorithm was used to achieve this milestone.
Rebalancing the immune system to treat autoimmune disease
Dr Nicolas Poirier reveals how immunotherapies can be designed to recalibrate the immune system for long-term maintenance of autoimmune remission.
Why invest in creating a modifiable drug framework?
Drug Target Review spoke with CUE Biopharma’s President and CSO to find out how and why they created the ImmunoSTAT platform and the ways it may benefit drug design in the future.
Could dolphins be viable models for human brain disorders?
Neuropathologic similarities between dolphins and humans suggest that the former could act as an effective model for the study of diseases such as Alzheimer’s. Professor Giovanni Di Guardo explains why dolphins could provide researchers with a new window into neurodegenerative conditons.
Novel molecules to adjust the circadian rhythm
A collaborative team of researchers has discovered two molecules that target the melatonin receptor, responsible for regulating the circadian rhythm. This article delves into their study and its therapeutic relevance for the body clock.
Discovering how drugs combat HIV and why resistance can occur
A group of researchers, led by Professor Zucai Suo, have revealed the mode of action of two HIV drugs and identified how resistance can develop, which they say could lead to improved drug design in the future.
ELRIG and the British Pharmacological Society: why form a strategic alliance?
Here, the benefits of collaborating in drug discovery are explored through the strategic alliance between ELRIG and the British Pharmacological Society.
Could the gut microbiome be the key to new antidepressant therapies?
Drug Target Review explores research that suggests the microbiome could be a therapeutic target for major depressive disorder and what treatment options are now in the pipeline as a result of this association.
Body-on-chip technology: resolving current limitations in drug discovery
Researchers have developed a new body-on-chip technology that can demonstrate the pharmacokinetics and pharmacodynamics of drugs in a pre-clinical setting without the need for animal testing.
The growing possibilities for stem cells in pharma
Drug Target Review explores the latest applications of stem cells in modelling disease, drug production and the most recent steps in regenerative medicine provided by research.
Developing an algorithm to predict drug-induced liver injury
A collaboration between Elsevier and the FDA will present an algorithm for the accurate prediction of drug-induced liver injury. Drug Target Review investigates the benefits this toxicology project will bring to the drug discovery industry.
Could novel sex-linked targets provide an autoimmunity therapy?
Recent research into why autoimmune disorders affect women four times more frequently than men has revealed several novel therapeutic targets that may lead to the development of future treatments.
Five of the latest cancer stem cell discoveries
Oncologic stem cells have been identified in many malignancies, and targeting these cells could help in the fight against cancer. Here are five of the most recent findings regarding cancer stem cells.
RNA and machine learning: rational design for multidimensional biomarkers
Modern day oncology therapies have seen significant innovation in the last decade. It is high time we commit to using biomarkers that are driven by rational design and the latest computational methods.